Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Breast Neoplasms 20Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Melanoma 3Lymphoma 3Lung Neoplasms 3Hematologic Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Recurrence 2Neoplasms 2Multiple Myeloma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Leukemia 2Healthy Participants 2Disease Progression 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × capivasertib × Clear all
NCT07281833 2026-02-27

CAPIcorn

West German Study Group

Phase 3 Recruiting
250 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

NCT02423603 2025-03-10

PAKT

Queen Mary University of London

Phase 2 Completed
71 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05348577 2025-01-27

CAPItello280

AstraZeneca

Phase 3 Active not recruiting
1,035 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

AstraZeneca

Phase 1 Completed
27 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡